When is workup indicated for persistent thrombocytosis?

When to Workup Persistent Elevated Platelets

Workup for persistent thrombocytosis is indicated when the platelet count is ≥450 × 10⁹/L confirmed on at least two separate samples, at which point immediate molecular testing for JAK2, CALR, and MPL mutations should be performed to distinguish primary (clonal) from secondary (reactive) causes. 1

Initial Confirmation and Verification

Before initiating any workup, confirm the thrombocytosis is real and persistent:

• Verify the sample does not contain clots and examine the peripheral smear to exclude platelet aggregates that may cause spurious elevation. 1
• Confirm platelet count ≥450 × 10⁹/L on at least two separate samples drawn on different occasions. 1
• Perform a complete blood count with peripheral smear to evaluate platelet morphology and identify other cellular abnormalities (e.g., teardrop cells suggesting myelofibrosis, dysplastic features suggesting myelodysplastic syndrome). 1, 2

When to Proceed with Molecular Testing

Immediate molecular testing for JAK2V617F, CALR (exon 9), and MPL mutations is the first essential diagnostic step once persistent thrombocytosis ≥450 × 10⁹/L is confirmed. 1 This threshold is lower than the older WHO 2001 criteria (≥600 × 10⁹/L) but aligns with revised 2007 WHO criteria and current practice. 3

Clinical Features That Lower the Threshold for Workup

Even with platelet counts below 450 × 10⁹/L, consider workup if:

• History of unexplained arterial or venous thrombosis (strongly predictive of essential thrombocythemia). 4
• Splenomegaly on examination or imaging. 1
• Unexplained bleeding despite normal or elevated platelet count. 1
• Microcirculatory symptoms (headaches, lightheadedness, acral paresthesias, erythromelalgia). 5
• Concomitant erythrocytosis or leukocytosis suggesting a myeloproliferative neoplasm. 2

Clinical Features Suggesting Secondary (Reactive) Thrombocytosis

Before ordering expensive molecular testing, assess for common secondary causes:

• Active malignancy, chronic inflammatory disease (e.g., rheumatoid arthritis, inflammatory bowel disease), splenectomy, or iron deficiency anemia are strongly associated with secondary thrombocytosis and may obviate the need for immediate molecular testing. 4
• Higher body mass index, elevated white blood cells, and neutrophilia favor reactive thrombocytosis. 4
• Lower hemoglobin, mean corpuscular volume (MCV), red cell distribution width (RDW), and mean platelet volume (MPV) suggest secondary causes. 4

In contrast, higher hemoglobin, MCV, RDW, and MPV favor essential thrombocythemia. 4

Molecular Testing Strategy

Approximately 80% of patients with essential thrombocythemia harbor at least one driver mutation (JAK2, CALR, or MPL) in a mutually exclusive manner. 1, 5 The overall yield of molecular testing in persistent thrombocytosis is approximately 52%, with 92% of positive results being JAK2, CALR, or MPL mutations. 4

• Request testing on whole blood or purified granulocytes. 1
• If initial driver mutations are negative but clinical suspicion remains high, consider extended mutational panel testing for TET2, ASXL1, DNMT3A, and SF3B1, which are present in approximately 50% of essential thrombocythemia patients. 1, 5

When to Refer to Hematology

Immediate hematology referral is recommended if:

• Platelet count >1,000 × 10⁹/L (extreme thrombocytosis carries bleeding risk from acquired von Willebrand syndrome). 1
• Presence of any driver mutation (JAK2, CALR, MPL). 1
• History of thrombosis or unexplained bleeding. 1
• Splenomegaly on examination or imaging. 1

Additional Diagnostic Testing in Primary Thrombocytosis

Once a myeloproliferative neoplasm is suspected or confirmed:

• Bone marrow biopsy is essential for definitive diagnosis and to distinguish essential thrombocythemia from prefibrotic myelofibrosis, which has different prognosis and management. 3, 2, 5
• Perform Doppler ultrasound of lower limbs to identify asymptomatic thrombosis. 1
• Consider abdominal imaging (ultrasound or venography) to exclude splenic or portal vein thrombosis. 1
• In extreme thrombocytosis (>1,000 × 10⁹/L), evaluate for acquired von Willebrand syndrome before initiating antiplatelet therapy. 1

Common Pitfalls to Avoid

• Do not dismiss the possibility of essential thrombocythemia solely because a secondary cause is present—the two can coexist if the first three WHO criteria are met. 3
• Do not delay molecular testing in patients with unexplained thrombosis or splenomegaly, even if a potential reactive cause exists. 4
• Do not overlook hyposplenia or asplenia (congenital or acquired from prior peritonitis, celiac disease, etc.) as a rare cause of persistent thrombocytosis; look for Howell-Jolly bodies on smear and small/absent spleen on imaging. 6
• Do not order costly next-generation sequencing panels indiscriminately—first assess for clinical features of secondary thrombocytosis (malignancy, inflammation, iron deficiency, splenectomy) to avoid overinvestigation. 4